PriceTargets.com logo

Krystal Biotech - KRYS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $228.14
  • Forecasted Upside: 2.79%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$221.96 As of 12/4/2025 05:00 PM ET
▲ +4.5 (2.07%)

This chart shows the closing price for KRYS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Krystal Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KRYS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KRYS

Analyst Price Target is $228.14
▲ +2.79% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $228.14, with a high forecast of $255.00 and a low forecast of $198.00. The average price target represents a 2.79% upside from the last price of $221.96.

This chart shows the closing price for KRYS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Krystal Biotech. This rating has held steady since August 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
11/25/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
11/19/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
11/13/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
11/4/2025CitigroupBoost TargetNeutral ➝ Neutral$166.00 ➝ $198.00
11/4/2025Chardan CapitalBoost TargetBuy ➝ Buy$216.00 ➝ $220.00
10/17/2025GuggenheimSet TargetBuy ➝ Buy$224.00
10/17/2025Bank of AmericaBoost TargetBuy ➝ Buy$182.00 ➝ $255.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$240.00
8/22/2025Chardan CapitalLower TargetBuy ➝ Buy$219.00 ➝ $216.00
8/22/2025HC WainwrightReiterated RatingBuy ➝ Buy$240.00
8/5/2025CitigroupReiterated RatingNeutral ➝ Neutral$176.00 ➝ $166.00
8/5/2025Chardan CapitalReiterated RatingBuy ➝ Buy$219.00
7/25/2025HC WainwrightReiterated RatingBuy ➝ Buy$240.00
7/25/2025Chardan CapitalReiterated RatingBuy ➝ Buy$219.00
7/22/2025Bank of AmericaLower TargetBuy ➝ Buy$193.00 ➝ $192.00
7/9/2025CitigroupReiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.00
6/24/2025HC WainwrightReiterated RatingBuy ➝ Buy$240.00
5/16/2025CitigroupLower TargetNeutral ➝ Neutral$215.00 ➝ $155.00
5/7/2025GuggenheimLower TargetBuy ➝ Buy$195.00 ➝ $189.00
5/7/2025Chardan CapitalReiterated RatingBuy ➝ Buy$219.00 ➝ $219.00
5/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$240.00 ➝ $240.00
4/28/2025HC WainwrightBoost TargetBuy ➝ Buy$221.00 ➝ $240.00
3/5/2025Jefferies Financial GroupInitiated CoverageBuy$245.00
2/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$221.00 ➝ $221.00
2/20/2025CitigroupBoost TargetNeutral ➝ Neutral$206.00 ➝ $215.00
2/20/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
2/20/2025Chardan CapitalBoost TargetBuy ➝ Buy$212.00 ➝ $218.00
2/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$221.00 ➝ $221.00
12/18/2024Chardan CapitalReiterated RatingBuy ➝ Buy$212.00 ➝ $212.00
12/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$221.00 ➝ $221.00
12/12/2024Chardan CapitalReiterated RatingBuy ➝ Buy$212.00 ➝ $212.00
12/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$221.00 ➝ $221.00
11/5/2024CitigroupBoost TargetNeutral ➝ Neutral$204.00 ➝ $206.00
11/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$221.00 ➝ $221.00
9/11/2024Stifel NicolausBoost TargetBuy ➝ Buy$204.00 ➝ $220.00
8/30/2024William BlairUpgradeStrong-Buy
8/29/2024Cantor FitzgeraldReiterated RatingOverweight
8/28/2024HC WainwrightBoost TargetBuy ➝ Buy$200.00 ➝ $221.00
8/12/2024Evercore ISIBoost TargetOutperform ➝ Outperform$201.00 ➝ $206.00
8/6/2024CitigroupReiterated RatingBuy ➝ Neutral$195.00 ➝ $204.00
8/5/2024Chardan CapitalBoost TargetBuy ➝ Buy$153.00 ➝ $208.00
8/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00
4/16/2024Stifel NicolausReiterated RatingBuy ➝ Buy$178.00 ➝ $204.00
2/27/2024GuggenheimBoost TargetBuy ➝ Buy$130.00 ➝ $175.00
2/27/2024CitigroupBoost TargetBuy ➝ Buy$160.00 ➝ $195.00
2/27/2024William BlairReiterated RatingOutperform
12/13/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$160.00 ➝ $180.00
11/20/2023The Goldman Sachs GroupInitiated CoverageBuy$160.00
11/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$100.00
10/12/2023CitigroupInitiated CoverageBuy$160.00
9/7/2023Berenberg BankInitiated CoverageBuy$154.00
8/7/2023Chardan CapitalBoost TargetBuy ➝ Buy$148.00 ➝ $153.00
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$139.00
5/24/2023Stifel NicolausBoost Target$102.00 ➝ $145.00
5/22/2023GuggenheimBoost Target$101.00 ➝ $130.00
5/22/2023Chardan CapitalBoost Target$133.00 ➝ $148.00
5/22/2023HC WainwrightBoost Target$119.00 ➝ $139.00
5/21/2023Bank of AmericaBoost Target$105.00 ➝ $118.00
4/17/2023Stifel NicolausInitiated CoverageBuy$102.00
3/22/2023William BlairReiterated RatingOutperform
2/28/2023GuggenheimReiterated RatingBuy$101.00
2/28/2023Chardan CapitalReiterated RatingBuy$133.00
2/28/2023HC WainwrightReiterated RatingBuy$119.00
2/28/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$79.00 ➝ $124.00
11/7/2022Chardan CapitalBoost TargetBuy$130.00 ➝ $133.00
11/7/2022HC WainwrightBoost TargetBuy$107.00 ➝ $119.00
8/24/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$74.00
8/9/2022Chardan CapitalLower TargetBuy$137.00 ➝ $130.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$91.00 ➝ $78.00
3/29/2022GuggenheimLower Target$114.00 ➝ $101.00
3/1/2022The Goldman Sachs GroupLower TargetBuy$125.00 ➝ $93.00
2/28/2022HC WainwrightLower TargetBuy$124.00 ➝ $107.00
1/18/2022Bank of AmericaInitiated CoverageBuy$110.00
11/30/2021The Goldman Sachs GroupBoost TargetBuy$85.00 ➝ $125.00
11/29/2021HC WainwrightBoost TargetPositive ➝ Buy$103.00 ➝ $124.00
7/20/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$73.00 ➝ $90.00
7/2/2021JonestradingReiterated RatingBuy$97.00
7/2/2021William BlairReiterated RatingBuy
7/1/2021Chardan CapitalReiterated RatingBuy
3/1/2021HC WainwrightBoost TargetBuy$84.00 ➝ $103.00
2/9/2021JonestradingInitiated CoverageBuy$97.00
1/8/2021HC WainwrightBoost TargetBuy$68.00 ➝ $84.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.19 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 31 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 24 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
6/7/2025
  • 12 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 32 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 31 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 15 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 19 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 29 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 29 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Krystal Biotech logo
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Read More

Today's Range

Now: $221.96
Low: $213.83
High: $222.66

50 Day Range

MA: $196.60
Low: $167.82
High: $221.96

52 Week Range

Now: $221.96
Low: $122.80
High: $222.66

Volume

406,327 shs

Average Volume

234,333 shs

Market Capitalization

$6.44 billion

P/E Ratio

33.28

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Krystal Biotech?

The following equities research analysts have issued stock ratings on Krystal Biotech in the last year: Bank of America Corporation, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., and Weiss Ratings.
View the latest analyst ratings for KRYS.

What is the current price target for Krystal Biotech?

0 Wall Street analysts have set twelve-month price targets for Krystal Biotech in the last year. Their average twelve-month price target is $228.14, suggesting a possible upside of 2.8%. Bank of America Corporation has the highest price target set, predicting KRYS will reach $255.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $198.00 for Krystal Biotech in the next year.
View the latest price targets for KRYS.

What is the current consensus analyst rating for Krystal Biotech?

Krystal Biotech currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KRYS.

What other companies compete with Krystal Biotech?

Other companies that are similar to Krystal Biotech include BioNTech, Genmab A/S, Revolution Medicines, Roivant Sciences and BridgeBio Pharma. Learn More about companies similar to Krystal Biotech.

How do I contact Krystal Biotech's investor relations team?

Krystal Biotech's physical mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company's listed phone number is (412) 586-5830 and its investor relations email address is [email protected]. The official website for Krystal Biotech is www.krystalbio.com. Learn More about contacing Krystal Biotech investor relations.